BIOMERICA INC
BMRA · XNASCIK 73290fmd_09D6BR4ZDKT87ZVJMR2S8E8WG3Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jun 01, 2010 to Aug 31, 2026, 65 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 6 | 5 | 7 | 7 | 19 | 5 | 5 | 5 | 4 |
| Total interest income | – | – | – | – | – | – | 0 | 0 | 0 | 1 |
| Cost of revenue | 4 | 4 | 4 | 5 | 7 | 16 | 5 | 5 | 5 | 4 |
| Gross profit | 2 | 2 | 1 | 2 | 0 | 3 | 0 | 1 | 0 | 0 |
| Research and development | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Selling, general and administrative | 2 | 2 | 2 | 3 | 6 | 6 | 6 | 5 | 5 | 5 |
| Total operating expenses | 3 | 3 | 4 | 4 | 8 | 8 | 8 | 7 | 6 | 6 |
| Operating income | (1) | (1) | (2) | (3) | (7) | (5) | (7) | (6) | (5) | (5) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Income before taxes | (1) | (1) | (2) | (3) | (7) | (5) | (7) | (6) | (5) | (4) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (1) | (2) | (3) | (7) | (5) | (7) | (6) | (5) | (4) |
| Net income | (1) | (1) | (2) | (3) | (7) | (5) | (7) | (6) | (5) | (4) |